Genetic heterogeneity in HER2/neu testing by fluorescence in situ hybridization: A study of 2522 cases

Modern Pathology

Volumn 25, Issue 5, 2012, Pages 683-688

  Chang, Martin C ^a,b   Malowany, Janet I ^a,b   Mazurkiewicz, Julita ^a   Wood, Martha ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

breast carcinoma; genetic heterogeneity; HER2 neu; in situ hybridization

Indexed keywords

ARTICLE; BREAST CARCINOMA; CELL NUCLEUS; CENTROMERE; CHROMOSOME 17; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETIC HETEROGENEITY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; TUMOR CELL; TUMOR VOLUME;

ADENOCARCINOMA; BREAST NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 84860459660     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.206     Document Type: Article

References (23)

1. Navolanic PM, Steelman LS, McCubrey JA. EGFR family signaling and its association with breast cancer development and resistance to chemotherapy. Int J Oncol 2003;22:237-252.
2. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182. (Pubitemid 17231334)
3. Pritchard KI, Shepherd LE, O'Malley FP, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006;354:2103-2111. (Pubitemid 43736610)
4. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353: 1659-1672. (Pubitemid 41464705)
5. Jagiello-Gruszfeld A, Tjulandin S, Dobrovolskaya N, et al. A single-arm phase II trial of first-line paclitaxel in combination with lapatinib in HER2-overexpressing metastatic breast cancer. Oncology 2010;79:129-135.
6. Jacobs TW, Gown AM, Yaziji H, et al. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 1999;17:1974-1982. (Pubitemid 29318824)
7. Jacobs TW, Gown AM, Yaziji H, et al. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999;17:1983-1987. (Pubitemid 29318825)
8. Pauletti G, Dandekar S, Rong HM, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000;18:3651-3664.
9. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145. (Pubitemid 350003059)
10. Tubbs RR, Hicks DG, Cook J, et al. Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experience. Diagn Mol Pathol 2007;16:207-210. (Pubitemid 350196977)
11. DowsettM, HannaWM, Kockx M, et al. Standardization of HER2 testing: results of an international proficiencytesting ring study. Mod Pathol 2007;20:584-591. (Pubitemid 46632000)
12. Glöckner S, Buurman H, Kleeberger W, et al. Marked intratumoral heterogeneity of c-myc and CyclinD1 but not of c-erbB2 amplification in breast cancer. Lab Invest 2002;82:1419-1427.
13. Shin SJ, Hyjek E, Early E, et al. Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray. Int J Surg Pathol 2006;14:279-284. (Pubitemid 44545764)
14. Hanna W, Nofech-Mozes S, Kahn HJ. Intratumoral heterogeneity of HER2/neu in breast cancer-a rare event. Breast J 2007;13:122-129. (Pubitemid 46280606)
15. Sukov WR, Miller DV, Duek AC, et al. Benefit of adjuvant trastuzumab in breast cancer patients with focal HER2 amplified colonies: data from N9831 Intergroup Adjuvant Trial [abstract]. J Clin Oncol 2009;27: 25s(Suppl):520.
16. Vance GH, Barry TS, Bloom KJ, et al. Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch Pathol Lab Med 2009;133:611-612.
17. Hsu C-Y, Li AF, Yang C-F, et al. Proposal of modification for the definition of genetic heterogeneity in HER2 testing in breast cancer [letter to the editor]. Arch Pathol Lab Med 2010;134:162.
18. Albarracin C, Edgerton ME, Gilcrease MZ, et al. Is it too soon to start reporting HER2 genetic heterogeneity [letter to the editor]? Arch Pathol Lab Med 2010;134: 162-163.
19. Vance GH, Hicks DG. In reply [letter to the editor]. Arch Pathol Lab Med 2010;134:163.
20. Bartlett AI, Starcynski J, Robson T, et al. Heterogeneous HER2 gene amplification: impact on patient outcome and a clinically relevant definition. Am J Clin Pathol 2011;136:266-274.
21. Theodosiou Z, Kasampalidis IN, Karayannopoulou G, et al. Evaluation of FISH image analysis system on assessing HER2 amplification in breast carcinoma cases. Breast 2008;17:80-84. (Pubitemid 351228789)
22. Turashvili G, Leung S, Turbin D, et al. Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis. BMC Cancer 2009;9:165.
23. Konsti J, Lundin J, Jumppanen M, et al. A publicdomain image processing tool for automated quantification of fluorescence in situ hybridisation signals. J Clin Pathol 2008;61:278-282. (Pubitemid 351354229)